YNL170W Antibody

What is YNL170W and why are antibodies against it used in research?

YNL170W is a putative uncharacterized protein in Saccharomyces cerevisiae (baker's yeast). Antibodies against this protein are valuable research tools for studying protein function, localization, and interactions within yeast cells. While YNL170W itself remains partially characterized, antibodies targeting it help researchers investigate its role in cellular processes and potentially identify novel functions. These antibodies are primarily used in techniques such as Western blotting, immunoprecipitation, and immunofluorescence to detect the presence, localization, and relative abundance of the YNL170W protein in experimental samples .

How are yeast-specific antibodies typically produced for research purposes?

Yeast-specific antibodies are produced through several methodologies:

• Yeast surface display (YSD): A widely used method where antibody fragments are expressed on the yeast cell surface using the a-agglutinin (Aga2) system. The antibody fragments are fused to Aga2 protein, which forms disulfide bonds with the cell wall-anchored Aga1 protein .

• Recombinant expression: Antibody genes can be cloned and expressed in E. coli, mammalian cells, or yeast systems to produce monoclonal antibodies or antibody fragments .

• Hybridoma technology: Traditional method involving immunization of animals (typically mice) with the yeast protein of interest, followed by fusion of antibody-producing B cells with myeloma cells to create stable antibody-producing cell lines .

For YNL170W specifically, recombinant antibody production is often preferred due to the challenges in purifying sufficient quantities of this native protein for immunization .

What formats of antibodies against yeast proteins are available for research?

Several antibody formats are available for yeast protein research, each with specific advantages:

For YNL170W specifically, scFv formats have shown utility in yeast surface display experiments, allowing detection of low-abundance proteins .

What are the optimal methods for validating YNL170W antibody specificity?

Validating YNL170W antibody specificity requires multiple complementary approaches:

• Western blot with YNL170W knockout control: Compare wild-type yeast lysate with a YNL170W knockout strain. A specific antibody will show a band at the expected molecular weight (as predicted from the amino acid sequence) in wild-type but not in knockout samples .

• Immunoprecipitation followed by mass spectrometry: Perform IP using the YNL170W antibody and identify pulled-down proteins by mass spectrometry. The primary hit should be YNL170W protein .

• Epitope mapping: Use synthetic peptides spanning different regions of YNL170W to determine which sequence the antibody recognizes, confirming target specificity .

• Cross-reactivity testing: Test against lysates from related yeast species to evaluate potential cross-reactivity with homologous proteins .

• Immunofluorescence with tagged protein: Compare antibody staining patterns with YNL170W-GFP fusion protein localization to confirm they match .

How should researchers optimize Western blotting protocols for yeast proteins like YNL170W?

Optimizing Western blotting for yeast proteins requires specific considerations:

• Cell lysis optimization:

  • Use glass bead disruption or enzymatic methods (zymolyase) to effectively break the yeast cell wall

  • Include protease inhibitors to prevent degradation of the target protein

  • Consider adding phosphatase inhibitors if studying phosphorylation status

• Gel percentage selection:

  • For YNL170W (~29 kDa), a 12-15% SDS-PAGE gel provides optimal resolution

• Transfer conditions:

  • Semi-dry transfer: 15V for 30-45 minutes

  • Wet transfer: 100V for 60 minutes or 30V overnight at 4°C

  • PVDF membranes often provide better results than nitrocellulose for yeast proteins

• Blocking optimization:

  • Test both BSA and non-fat milk (3-5%) to determine which gives lower background

  • For phospho-specific antibodies, always use BSA as milk contains casein phosphoproteins

• Antibody dilution ranges:

  • Primary antibody: Start with 1:1000 dilution and optimize

  • Secondary antibody: Typically 1:5000 to 1:10000

• Loading control selection:

  • PGK1 (phosphoglycerate kinase, 43 kDa)

  • GAPDH (37 kDa)

  • Histone H3 (for nuclear proteins, 15 kDa)

What are the key considerations when using YNL170W antibodies for immunoprecipitation?

When performing immunoprecipitation with YNL170W antibodies, consider:

• Antibody conjugation:

  • Pre-conjugate antibodies to beads (Protein A/G or magnetic) for cleaner results

  • If using direct capture, use gentle wash buffers to avoid losing antibody-antigen complexes

• Lysis buffer selection:

  • For studying protein-protein interactions: Use mild non-ionic detergents (0.1-0.5% NP-40 or Triton X-100)

  • For studying post-translational modifications: Include appropriate inhibitors (phosphatase, deacetylase, etc.)

• Crosslinking considerations:

  • For transient interactions: Consider formaldehyde crosslinking (0.1-1%) before lysis

  • Validate crosslinking conditions to avoid artifacts

• Controls to include:

  • IgG control (same species as the antibody)

  • Input sample (pre-IP lysate)

  • YNL170W knockout strain if available

• Elution methods:

  • Denaturing: SDS buffer at 95°C (disrupts all interactions)

  • Native: Excess peptide competition (if epitope is known)

  • pH elution: Glycine buffer pH 2.5 (often preserves interactions)

How can yeast surface display be used to develop improved antibodies against YNL170W?

Yeast surface display (YSD) offers a powerful platform for antibody engineering against YNL170W:

• Library construction and screening:

  • Create a diverse scFv library (>10^7 variants) through random mutagenesis or CDR-focused mutagenesis

  • Express library on yeast surface as Aga2 fusions

  • Screen using fluorescence-activated cell sorting (FACS) with decreasing concentrations of labeled YNL170W protein

  • Perform multiple rounds of selection to isolate high-affinity binders

• Affinity maturation protocol:

  • Start with a lead antibody candidate

  • Introduce targeted mutations in CDR regions

  • Use error-prone PCR for random mutagenesis

  • Perform selections with increasingly stringent washing steps

  • Sequence selection outputs to identify beneficial mutations

• Format conversion:

  • Convert selected scFv to various formats (IgG, Fab, VHH) for different applications

  • Test functionality in each format as binding properties may change

Research data shows that optimized antibody fragments can achieve nanomolar to picomolar affinities against yeast proteins using this approach (e.g., Fab cb2-6 achieved 5.4×10^-10 M affinity) .

What are the applications of anti-YNL170W antibodies in studying protein-protein interactions in yeast?

Anti-YNL170W antibodies enable several advanced approaches for studying protein-protein interactions:

• Co-immunoprecipitation coupled with mass spectrometry:

  • Use anti-YNL170W antibodies to pull down the protein complex

  • Analyze by MS to identify interaction partners

  • Compare results with yeast two-hybrid data to validate interactions

• Proximity-dependent labeling:

  • Create YNL170W fusion with BioID or APEX2

  • Use anti-YNL170W antibodies to confirm proper expression and localization

  • Identify proximal proteins through biotinylation patterns

• Single-molecule co-localization:

  • Combine anti-YNL170W antibodies with antibodies against potential interactors

  • Use super-resolution microscopy to detect co-localization events

  • Quantify interaction frequency in different cellular conditions

• Förster resonance energy transfer (FRET):

  • Label anti-YNL170W with donor fluorophore

  • Label antibodies against potential interactors with acceptor fluorophore

  • Measure FRET signal to confirm close proximity (<10 nm) in vivo

These approaches can help map the YNL170W interactome within the broader yeast protein interaction network, potentially revealing associations with the 4,549 two-hybrid interactions identified in comprehensive analyses .

How can computational approaches improve antibody design for yeast proteins like YNL170W?

Recent advances in computational antibody design offer promising approaches for yeast proteins:

• AI-based structure prediction and binding simulation:

  • Use AlphaFold2 or RoseTTAFold2 to predict YNL170W structure

  • Apply computational docking to predict antibody-antigen interactions

  • Filter designs based on predicted binding energy and specificity

• De novo antibody design:

  • Use RFdiffusion to design antibody scaffolds targeting specific YNL170W epitopes

  • Optimize CDR loops for desired binding properties

  • Fine-tune sequence with ProteinMPNN

• Epitope mapping and accessibility analysis:

  • Identify surface-exposed regions of YNL170W

  • Calculate antigenicity scores for potential epitopes

  • Design antibodies targeting conserved vs. variable regions based on research needs

Recent research demonstrated successful de novo design of antibodies against viral targets, with experimental validation showing accurate atomic-level targeting as confirmed by cryo-EM structures, suggesting similar approaches could work for yeast proteins .

What are common challenges when working with antibodies against low-abundance yeast proteins like YNL170W?

Researchers commonly encounter these challenges with low-abundance yeast proteins:

• Low signal intensity in Western blots:

  • Solution: Enrich samples through fractionation or immunoprecipitation

  • Use highly sensitive detection methods (ECL Prime, fluorescent secondaries)

  • Increase protein loading (50-100 μg total protein)

  • Consider signal amplification systems (tyramide signal amplification)

• Non-specific binding:

  • Solution: Increase blocking concentration (5% BSA or milk)

  • Pre-adsorb antibody with yeast knockout lysate

  • Use monoclonal antibodies or affinity-purified polyclonals

  • Optimize wash stringency (increase salt concentration or add 0.1% SDS)

• Protein degradation:

  • Solution: Use fresh samples with complete protease inhibitor cocktails

  • Process samples quickly at 4°C

  • Consider adding specific inhibitors based on YNL170W properties

• Inconsistent results:

  • Solution: Standardize growth conditions for yeast cultures

  • Use internal loading controls for normalization

  • Implement quantitative Western blotting with standard curves

  • Perform biological and technical replicates (minimum n=3)

How should researchers address cross-reactivity with other yeast proteins when using YNL170W antibodies?

Cross-reactivity issues can be addressed through these methodological approaches:

• Epitope analysis:

  • Conduct BLAST searches to identify yeast proteins with similar epitopes

  • Test antibody against these potential cross-reactive proteins individually

  • Use peptide competition assays to confirm epitope specificity

• Validation with multiple techniques:

  • Compare results across Western blot, immunofluorescence, and IP

  • Different techniques may show different cross-reactivity patterns

  • Consistent results across methods increase confidence

• Genetic controls:

  • Use YNL170W knockout as negative control

  • Use YNL170W overexpression as positive control

  • Create epitope-tagged YNL170W constructs for parallel validation

• Antibody purification:

  • Perform affinity purification against specific YNL170W epitopes

  • Use negative selection against cross-reactive proteins

  • Consider developing single-domain antibodies (VHHs) for improved specificity

What statistical approaches should be used when analyzing quantitative data from YNL170W antibody experiments?

• Western blot quantification:

  • Normalize to appropriate loading controls (GAPDH, PGK1, actin)

  • Use integrated density measurements rather than peak intensity

  • Apply background subtraction using adjacent areas

  • For time-course experiments, normalize to t=0 or control condition

• Sample size determination:

  • Power analysis: For detecting 50% change with 80% power, minimum n=3-5

  • Account for biological and technical variability in yeast systems

• Statistical tests and visualizations:

  • For comparing two conditions: paired t-test or Wilcoxon signed-rank test

  • For multiple conditions: ANOVA with appropriate post-hoc tests

  • Report effect sizes and confidence intervals, not just p-values

  • Use box plots or violin plots rather than bar graphs to show data distribution

• Reproducibility considerations:

  • Report antibody validation results

  • Document batch effects and how they were controlled

  • Consider blind analysis when possible

  • Share raw data and analysis scripts

How might single-domain antibodies (nanobodies) against YNL170W advance yeast proteomics research?

Single-domain antibodies offer several advantages for yeast proteomics:

• Intracellular expression:

  • VHHs can fold correctly in the reducing environment of the cytoplasm

  • Can be expressed directly in yeast cells as intrabodies

  • Enable live-cell imaging and functional perturbation of YNL170W

  • Allow dynamic monitoring of protein localization and interactions

• Improved spatial resolution:

  • Small size (~15 kDa vs. 150 kDa for IgG) allows closer epitope approach

  • Reduces "label displacement error" in super-resolution microscopy

  • Enables precise localization of YNL170W within yeast ultrastructure

  • Better penetration into complex yeast protein assemblies

• Affinity capture applications:

  • VHH-based capture reagents for YNL170W can be immobilized at higher density

  • Higher thermal and chemical stability enables more stringent conditions

  • Can be engineered with site-specific conjugation sites for oriented immobilization

  • Potential for multiplexed capture of YNL170W and its interaction partners

Recent research has demonstrated successful de novo design of VHHs with nanomolar affinities against various targets, suggesting similar approaches could be applied to YNL170W .

What are the implications of using humanized antibodies against YNL170W for advanced research applications?

Humanized antibodies provide several advantages in research contexts:

• Reduced immunogenicity in mammalian systems:

  • Enables long-term studies in mammalian cells expressing YNL170W homologs

  • Allows use in xenograft models expressing yeast proteins

  • Reduces background in human tissue samples when studying yeast infections

• Improved antibody engineering compatibility:

  • Humanized scaffolds are compatible with existing human antibody libraries

  • Better framework for further modifications (e.g., bispecifics, ADCs)

  • More predictable biophysical properties in mammalian expression systems

• Research continuity:

  • Same antibody can be used from basic research through translational studies

  • Reduces variables when comparing results across experimental systems

  • Consistent binding properties across different detection platforms

• Methodological approaches:

  • Resurfacing: Replace surface-exposed murine residues with human counterparts

  • CDR grafting: Transfer binding regions to human framework

  • Rational design: Computationally optimize humanization strategy

How can active learning approaches improve the efficiency of antibody development against yeast proteins?

Active learning strategies offer promising improvements in antibody development efficiency:

• Experimental design optimization:

  • Use machine learning to identify optimal antibody-antigen pairs for testing

  • Prioritize experiments based on information gain rather than random selection

  • Iteratively improve predictive models with new experimental data

• Implementation methodology:

  • Begin with diverse antibody library against YNL170W

  • Test small subset and measure binding properties

  • Use results to train initial prediction model

  • Select next round of candidates that maximize information gain

  • Repeat process until optimal antibodies are identified

• Performance metrics:

  • Area under the active learning curve (ALC) to measure efficiency improvement

  • ROC AUC on test datasets to evaluate prediction quality

  • Comparison against random selection baseline

Research data shows that active learning approaches can significantly reduce the number of experiments needed to identify optimal antibody-antigen pairs, with performance improvements of 20-50% compared to random selection strategies .

How can CRISPR-based approaches complement antibody techniques when studying YNL170W?

CRISPR technologies offer powerful complementary approaches:

• Validation controls creation:

  • Generate precise YNL170W knockouts for antibody validation

  • Create epitope-tagged YNL170W strains at endogenous loci

  • Develop inducible expression systems for controlled studies

• Functional studies:

  • Use CRISPRi to reduce YNL170W expression without complete knockout

  • Apply CRISPRa to upregulate YNL170W in specific conditions

  • Generate domain-specific mutations to map antibody epitopes

• Integrated approaches:

  • Combine CRISPR screens with antibody-based detection

  • Use antibodies to validate CRISPR editing efficiency

  • Apply both techniques to study YNL170W interaction networks

• Temporal control:

  • Optogenetic or chemical-inducible CRISPR systems for acute manipulation

  • Use antibodies to measure kinetics of protein level changes

  • Track protein dynamics following CRISPR perturbation

What are the best practices for combining flow cytometry with YNL170W antibodies for quantitative analysis?

Optimizing flow cytometry with YNL170W antibodies requires:

• Sample preparation optimization:

  • Cell wall permeabilization: Test zymolyase concentrations (0.5-5 U/mL)

  • Fixation: Compare paraformaldehyde (1-4%) vs. methanol fixation

  • Permeabilization: Optimize Triton X-100 (0.1-0.5%) or saponin (0.1-1%)

  • Blocking: Use 2-5% BSA with 5-10% normal serum from secondary antibody species

• Staining protocol development:

  • Titrate antibody concentration (typically 0.1-10 μg/mL)

  • Optimize staining time and temperature (4°C vs. room temperature)

  • Test different secondaries or directly conjugated primaries

  • Include FcR blocking reagents to reduce non-specific binding

• Controls and gating strategy:

  • Unstained cells for autofluorescence baseline

  • Secondary-only for background assessment

  • YNL170W knockout as negative control

  • Single-color controls for compensation

  • Viability dye to exclude dead cells

• Quantitative analysis:

  • Use calibration beads to convert fluorescence to molecules of equivalent soluble fluorochrome (MESF)

  • Apply standardized gating across experiments

  • Report both percentage positive and median fluorescence intensity

  • Consider dimensionality reduction techniques for complex datasets

Research data shows successful yeast surface display applications with detection of >25% positive cells and clear separation between positive and negative populations .

How can researchers effectively combine structural biology approaches with antibody development for yeast proteins?

Integrating structural biology and antibody development offers synergistic benefits:

• Structure-guided epitope selection:

  • Use AlphaFold2 or RoseTTAFold2 to predict YNL170W structure

  • Identify surface-exposed, structured epitopes

  • Target conserved functional domains for potential inhibitory antibodies

  • Select epitopes that minimize cross-reactivity with related proteins

• Antibody-assisted structural studies:

  • Use antibodies as crystallization chaperones for YNL170W

  • Stabilize specific conformations of the protein

  • Generate Fab fragments for cryo-EM studies

  • Validate computational models with experimental structural data

• Epitope mapping approaches:

  • Hydrogen-deuterium exchange mass spectrometry (HDX-MS) to identify binding regions

  • X-ray crystallography of antibody-antigen complexes

  • Cryo-EM of larger complexes or flexible proteins

  • Computational docking validated by mutagenesis

• Structure-based antibody engineering:

  • Use structural data to optimize antibody-antigen interface

  • Engineer antibodies that recognize specific protein conformations

  • Design bispecific antibodies targeting YNL170W and its interaction partners

  • Apply computational design to improve affinity and specificity